Redx Pharma (GB:REDX) has released an update.
Redx Pharma, a clinical-stage biotechnology company, has announced the upcoming delisting of its ordinary shares from the AIM market, set to take effect on May 1, 2024. Shareholders will still be able to trade shares through a matched bargain facility provided by J P Jenkins, detailed on the company’s website. The company, known for developing targeted therapeutics for fibrotic diseases and cancer, is progressing with several clinical trials and strategic partnerships.
For further insights into GB:REDX stock, check out TipRanks’ Stock Analysis page.
